How Do You Really Feel About Your Father? Choice Guide (I Love My Dad) Should You Cut Coupe or Sonar from the Team in Dispatch Episode 3? Should You Have Dinner with Blazer or Movies with Invisigal in ...
Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...
Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...
Orbital Therapeutics is currently running IND-enabling studies for its lead candidate. (iStock / Getty Images Plus) The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing ...
Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio. Bristol Myers ...
A mobile phone app designed to deliver suicide-specific therapy reduced suicidal behavior among high-risk psychiatric inpatients, according to a new study by scientists at Yale School of Medicine and ...
OTX Boxing Atlanta delivered a spectacular return to the city as OTX 15 electrified The Tabernacle on July 25. This highly anticipated event wasn’t just another night of fights; it was a demonstration ...
AbbVie will pay US$2.1 billion to acquire Capstan Therapeutics and its in vivo CAR T technology, which uses mRNA-loaded lipid nanoparticles (LNPs) to reprogramme immune cells. Capstan’s lead asset is ...
Atlanta, GA (July 1, 2025) Overtime Boxing (OTX), The Platform for the Next Generation of Boxers, returns to Atlanta, GA on Friday, July 25 with a stellar eight-fight card at Tabernacle headlined by a ...
Shane Limbaugh is a Contributor at DualShockers who began covering games professionally in 2025. A longtime gamer with a Bachelor’s Degree in Game Design and Criticism, Shane brings a design-focused ...
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results